Targeted Drug Shrinks Tumors In Hard-To-Treat Cancer

A targeted antibody-drug conjugate shrank tumors in women with recurrent or persistent uterine cancer after standard treatments failed.

In the clinical trial, some patients with aggressive disease had complete responses, while many others had stable disease for at least six months.

The treatment delivered chemotherapy directly into cancer cells and had manageable side effects.

The results point to a new option for hard-to-treat uterine cancer and add momentum to antibody-drug conjugates in oncology.